Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Sirtuin enzymes (SIRT1 and SIRT2) have context-dependent roles in cancer, acting as both tumor promoters and suppressors.
• Inhibition of SIRT1 or SIRT2 demonstrates antitumor potential in various cancer models.
• Simultaneous SIRT1/2 inhibition offers a therapeutic strategy by blocking p53 deacetylation, but few dual inhibitors exist.

Purpose of the Study:

• To discover novel small molecules that simultaneously inhibit both SIRT1 and SIRT2.
• To evaluate the antiproliferative and pro-apoptotic effects of these novel dual inhibitors in leukemia models.

Main Methods:

• Rational drug design incorporating virtual screening and substructure search.
• Biochemical assays to determine inhibitory activity (IC50) and specificity against SIRT1 and SIRT2.
• In vitro studies on human leukemia cell lines (e.g., MOLM-13) to assess apoptosis induction and antiproliferative effects.

Main Results:

• Eleven novel compounds demonstrated high inhibitory activity (IC50 < 5 μM) and specificity for both SIRT1 and SIRT2.
• Compounds hsa55 and PS9 exhibited significant antiproliferative effects and induced apoptosis in leukemia cell lines.
• Increased p53 and α-tubulin acetylation was observed in MOLM-13 cells treated with hsa55 and PS9.

Conclusions:

• The identified novel scaffolds are potent SIRT1/2 dual inhibitors.
• These compounds show significant efficacy against leukemia cell lines, suggesting therapeutic potential.
• The findings provide a basis for developing new anti-leukemia drugs targeting SIRT1 and SIRT2.